Home

MPM Oncology Impact Management GP LLC

CIK 1721035 · last filed 2021-08-25

MPM Oncology Impact Management GP LLC is a corporate insider who has filed 6 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing shows the insider sold $12.4M of CGEM on Aug 25, 2021. Across all open-market trades the lifetime net is −$7.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $165.0M across reported positions. The firm reports its address in Cambridge, MA. 32 SEC filings were submitted jointly with MPM BioImpact LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$165.02M

Companies

2

Total Filings

6

Lifetime Open-Market Net

-$7.60M

Filer Profile

Reported Address
450 KENDALL STREET
CAMBRIDGE, MA 02142
Phone
(617) 425-9200
State of Incorporation
DE
Related Filers
MPM BioImpact LLC — 32 joint filings, latest 2021-08-25
Oncology Impact Fund (Cayman) Management L.P. — 32 joint filings, latest 2021-08-25
UBS Oncology Impact Fund L.P. — 32 joint filings, latest 2021-08-25
ANSBERT GADICKE — 19 joint filings, latest 2021-06-02
MPM ONCOLOGY INNOVATIONS FUND LP — 2 joint filings, latest 2021-05-06
MPM Oncology Innovations Fund GP LLC — 2 joint filings, latest 2021-05-06
MPM ASSET MANAGEMENT INVESTORS BV2018 LLC — same reported address
MPM BIOVENTURES 2018 (B), L.P. — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CGEM 10%+ Owner 7,858,018 $21.00 $165.02M $12.79M 2 2021-08-25
Harpoon Therapeutics, Inc. (HARP) Delisted 10%+ Owner 640,275 $23.01 $14.73M -$20.40M 4 2021-05-24

Recent Filings

6 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2021-08-25 CGEM Sell (S) −423,576 -$12.41M EDGAR
2021-05-24 Harpoon Therapeutics, Inc. (HARP) Delisted Sell (S) −79,535 -$1.61M EDGAR
2021-04-29 Harpoon Therapeutics, Inc. (HARP) Delisted Sell (S) −650,715 -$14.31M EDGAR
2021-04-22 Harpoon Therapeutics, Inc. (HARP) Delisted Sell (S) −44,860 -$851.1K EDGAR
2021-04-20 Harpoon Therapeutics, Inc. (HARP) Delisted Sell (S) −190,760 -$3.63M EDGAR
2021-01-14 CGEM Mixed +31,655,548 $25.20M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.